Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab, Pemetrexed, and Erlotinib in Elderly Advanced NSCLC
NCT00351039Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Jul 2006
- Primary completion
- Sep 2008
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab, pemetrexed and erlotinib in non-small cell lung cancer (NSCLC), sponsored by Moffitt Cancer Center. Primary endpoint: Progression Free Survival at 26 months. Started Jul 2006; status: terminated.
02
Drugs
bevacizumabpemetrexederlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00351039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00351039.